EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis

Mina Hannan, Leila Jabalameli, Mohammad Reza Aghasadeghi, Naser Harzandi, Seyed Mehdi Sadat

Journal of Medical Microbiology and Infectious Diseases · 2023

DOI: 10.61186/jommid.11.3.128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology and Infectious Diseases, 2023. Verfasst von Mina Hannan und 4 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis A virus (HAV) is a causative agent of acute hepatitis in humans, infecting more than one million individuals every year, including both symptomatic and asymptomatic infections.The currently available preventive vaccines for HAV are based on either wild-type or live-attenuated virus strains, which can contribute to the costliness of the vaccination process.Therefore, it may be worthwhile to explore the potential of subunit vaccines that utilize immunogenic viral products.

Methods

This study presents the results of a novel recombinant protein production study that employed the native structures of HAV-VP1 and HBs-Ag.The fusion protein underwent comprehensive characterization to evaluate its potential applications in diagnostics and immunization.The truncated recombinant protein, HAV-VP1 (position 99-259 aa) -HBs-Ag, was successfully expressed in the Escherichia coli BL21-DE3 system.

Results

The recombinant protein, with a molecular weight of 46 kDa, was evaluated using SDS-PAGE gel electrophoresis and confirmed by western blotting.The fusion protein was successfully detected in serum samples positive for HBV or HAV using anti-HBs and anti-VP1 antibodies.Additionally, it elicited a potent humoral response in BALB/c mice.

Conclusion

The novel recombinant protein described in this study has the potential to serve as a bivalent vaccine against HAV and HBV infections.The next step involves evaluating the immunogenicity and safety profile of the protein.

Zitieren

APA

Hannan, M., Jabalameli, L., Aghasadeghi, M. R., Harzandi, N., & Sadat, S. M. (2023). Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis. Journal of Medical Microbiology and Infectious Diseases. https://doi.org/10.61186/jommid.11.3.128

Vancouver

Hannan M, Jabalameli L, Aghasadeghi MR, Harzandi N, Sadat SM. Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis. Journal of Medical Microbiology and Infectious Diseases. 2023. doi:10.61186/jommid.11.3.128

BibTeX
@article{Hannan2023,
  author = {Hannan, Mina and Jabalameli, Leila and Aghasadeghi, Mohammad Reza and Harzandi, Naser and Sadat, Seyed Mehdi},
  title = {Expression and Evaluation of a Novel HAV-VP1 and HBS-Ag Fusion Protein for Potential Applications in Immunization and Diagnosis},
  journal = {Journal of Medical Microbiology and Infectious Diseases},
  year = {2023},
  doi = {10.61186/jommid.11.3.128}
}
Kostenlos starten →